Biotheranostics’ Breast Cancer Index® predicts benefit from two-and-a-half versus five years of extended endocrine therapy in HR+ ...
San Diego, CA, May 15, 2020 (GLOBE NEWSWIRE) -- Novel evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine response in distinct subgroups of HR+ early stage breast cancer patients will be premiered at ASCO 2020. The …